413 related articles for article (PubMed ID: 32042736)
1. Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
Jia L; Dong X; Yang J; Jia R; Zhang H
Ann Transl Med; 2019 Dec; 7(23):720. PubMed ID: 32042736
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis.
Wang L; Yin H; Yang L; Zhang F; Wang S; Liao D
Front Pharmacol; 2022; 13():779694. PubMed ID: 35559232
[No Abstract] [Full Text] [Related]
3. Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat.
Tang M; Zhu C; Yan T; Zhou Y; Lv Q; Chuan J
Front Pharmacol; 2021; 12():658079. PubMed ID: 34276361
[No Abstract] [Full Text] [Related]
4. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis.
Zheng Q; Yang H; Fu X; Huang Y; Wei R; Wang Y; Liu YN; Liu WJ
Nephrol Dial Transplant; 2021 Aug; 36(9):1603-1615. PubMed ID: 33051677
[TBL] [Abstract][Full Text] [Related]
5. Roxadustat regulates iron metabolism in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A meta-analysis.
Hou YP; Wang C; Mao XY; Zhang MZ; Li B
J Formos Med Assoc; 2022 Nov; 121(11):2288-2299. PubMed ID: 35871036
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of roxadustat for the treatment of anemia in non-dialysis chronic kidney disease patients: A systematic review and meta-analysis of randomized double-blind controlled clinical trials.
Chen T; Huang J; Dong H; Xu L; Chen C; Tang Y; Huang W
Front Nutr; 2022; 9():1029432. PubMed ID: 36466382
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Roxadustat in Patients with Chronic Kidney Disease: An Updated Meta-Analysis of Randomized Controlled Trials including 6,518 Patients.
Lei J; Li H; Wang S
Biomed Res Int; 2022; 2022():2413176. PubMed ID: 36420092
[TBL] [Abstract][Full Text] [Related]
8. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
Liu J; Zhang A; Hayden JC; Bhagavathula AS; Alshehhi F; Rinaldi G; Kontogiannis V; Rahmani J
Pharmacol Res; 2020 May; 155():104747. PubMed ID: 32171893
[TBL] [Abstract][Full Text] [Related]
9. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.
Zheng L; Tian J; Liu D; Zhao Y; Fang X; Zhang Y; Liu Y
Br J Clin Pharmacol; 2022 Mar; 88(3):919-932. PubMed ID: 34428860
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
Zhang S; Guo J; Xie S; Chen J; Yu S; Yu Y
Int Urol Nephrol; 2021 Jun; 53(6):1139-1147. PubMed ID: 33026571
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of roxadustat treatment for anemia in patients with kidney disease: a meta-analysis and systematic review.
Qie S; Jiao N; Duan K; Li J; Liu Y; Liu G
Int Urol Nephrol; 2021 May; 53(5):985-997. PubMed ID: 33389461
[TBL] [Abstract][Full Text] [Related]
13. Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD.
Pergola PE; Charytan C; Little DJ; Tham S; Szczech L; Leong R; Fishbane S
Kidney360; 2022 Sep; 3(9):1511-1528. PubMed ID: 36245647
[TBL] [Abstract][Full Text] [Related]
14. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis.
Liu C; Fu Z; Jiang J; Chi K; Geng X; Mao Z; Song C; Sun G; Hong Q; Cai G; Chen X; Sun X
Front Med (Lausanne); 2021; 8():724456. PubMed ID: 34532333
[No Abstract] [Full Text] [Related]
16. Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review.
Damarlapally N; Thimmappa V; Irfan H; Sikandari M; Madhu K; Desai A; Pavani P; Zakir S; Gupta M; Khosa MM; Kotak S; Varrassi G; Khatri M; Kumar S
Cureus; 2023 Oct; 15(10):e47430. PubMed ID: 38021836
[TBL] [Abstract][Full Text] [Related]
17. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors
Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X
Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953
[TBL] [Abstract][Full Text] [Related]
18. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Renal Anemia: A Meta-Analysis of Randomized Trials.
Wen T; Zhang X; Wang Z; Zhou R
Nephron; 2020; 144(11):572-582. PubMed ID: 32866960
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of Roxadustat for the treatment of anemia in dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials.
Abdelazeem B; Abbas KS; Shehata J; El-Shahat NA; Baral N; Savarapu P; Kunadi A
Ann Transl Med; 2021 Dec; 9(23):1714. PubMed ID: 35071408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
